(4-(4-(trifluoromethyl)phenoxy)benzoyl)glycine | 915018-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(4-(trifluoromethyl)phenoxy)benzoyl)glycine
• 英文别名: N-{4-[4-(trifluoromethyl)phenoxy]benzoyl}glycine；2-[[4-[4-(trifluoromethyl)phenoxy]benzoyl]amino]acetic acid
• CAS: 915018-20-1
• 化学式: C₁₆H₁₂F₃NO₄
• 分子量: 339.271
• InChiKey: CSOSSLROMXXFGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl 2-({4-[4-(trifluoromethyl)phenoxy]phenyl}formamido)acetate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 以93.6 %的产率得到(4-(4-(trifluoromethyl)phenoxy)benzoyl)glycine
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  [FR] COMPOSÉS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES MÉDIÉS PAR LE COMPLÉMENT

  摘要：

  This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.

  公开号：

  WO2023183405A2

文献信息

• SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Aoki Kazumasa

  公开号：US20090118199A1

  公开（公告）日：2009-05-07

  A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R 1 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R 2 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C 1 -C 6 alkoxy group].

  一种药物组合物，其包括以下化合物或其药学上可接受的盐作为活性成分：[其中，R1是C6-C10芳基，可以被取代为一个或多个从取代基α中选择的基团；R2是C6-C10芳基，可以被取代为一个或多个从取代基α中选择的基团；X是羟基或C1-C6烷氧基。]
• Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same
  申请人：Aoki Kazumasa

  公开号：US20120220593A1

  公开（公告）日：2012-08-30

  A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R 1 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R 2 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C 1 -C 6 alkoxy group].

  一种制药组合物，包括具有式（I）或其药理学上可接受的盐作为活性成分的化合物：[其中，R1是例如C6-C10芳基基团，该基团可以被选自取代基α的一个或多个基团替代；R2是例如C6-C10芳基基团，该基团可以被选自取代基α的一个或多个基团替代；X是例如羟基或C1-C6烷氧基。]
• Substituted propanamide derivative and pharmaceutical composition containing the same
  申请人：Daiichi Sankyo Company, Limited

  公开号：US08344029B2

  公开（公告）日：2013-01-01

  It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; R2 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; and X represents a hydroxyl group or a C1-C6 alkoxy group, for example].

  本发明的目的是提供一种替代的丙酰胺衍生物或其药理学上可接受的盐，其可用作骨代谢疾病的预防或治疗剂。本发明涉及一种制药组合物，其包含具有通式(I)的化合物或其药理学上可接受的盐作为活性成分：[其中，R1代表C6-C10芳基，该芳基可以被从取代基组α中选择的基团取代，例如；R2代表C6-C10芳基，该芳基可以被从取代基组α中选择的基团取代，例如；X代表羟基或C1-C6烷氧基，例如]。
• SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1908466B1

  公开（公告）日：2014-02-19
• US8143446B2
  申请人：——

  公开号：US8143446B2

  公开（公告）日：2012-03-27